The Market Reports

Synopsis
The global market for Peptide CDMO was estimated to be worth US$ 4235 million in 2024 and is forecast to a readjusted size of US$ 11080 million by 2031 with a CAGR of 15.0% during the forecast period 2025-2031.
Peptides are synthesized by coupling the carboxyl group of one amino acid to the amino group of another amino acid molecule. Due to the possibility of unintended reactions, protecting groups are common necessary. Chemical peptide synthesis most commonly starts at the carboxyl end of the peptide, and thus progress toward the amino-terminus. This is the opposite direction of protein biosynthesis. A contract development and manufacturing company (CDMO) is a company within the pharmaceutical industry that provides drug development and manufacturing services. Pharmaceutical companies partner with CDMOs as a way to outsource drug development and drug manufacturing. CDMO peptides production via contract peptide manufacturing is to optimize process development and achieve highly efficient conversion at every amino acid coupling to produce a high-purity crude synthetic custom peptide and minimize the demands on downstream processing.
The Peptide CDMO (Contract Development and Manufacturing Organization) market is driven by the increasing demand for peptide-based therapeutics. Peptides are gaining significant traction in the pharmaceutical industry due to their high specificity, targeted action, and fewer side effects compared to traditional small-molecule drugs. As a result, there is growing interest in developing and manufacturing peptides for a wide range of indications, including oncology, diabetes, cardiovascular diseases, and neurological disorders. This shift is coupled with the rise in personalized medicine, where peptides are seen as promising candidates for tailored therapies. Peptide CDMOs are playing a crucial role by providing specialized services like synthesis, purification, and formulation, enabling pharmaceutical companies to bring peptide-based drugs to market faster and more efficiently. Additionally, advancements in peptide synthesis technologies and the increasing outsourcing trend by biopharmaceutical companies are fueling growth in this sector.
Despite the positive growth drivers, the Peptide CDMO market faces several challenges. One of the main hurdles is the complexity involved in peptide synthesis and manufacturing, particularly for large-scale production. Peptides are often fragile and prone to degradation, requiring strict control over production processes, which can be both time-consuming and costly. Additionally, the high costs of peptide synthesis, purification, and formulation pose significant barriers to entry for smaller players, limiting competition and innovation in the market. Furthermore, regulatory challenges are a concern, as peptides often face more stringent requirements during the clinical development and commercialization stages compared to traditional small-molecule drugs. These challenges can result in delays in drug development and increased production costs, which could ultimately impact the profitability of peptide CDMOs.
Global key peptide CDMO producers include Bachem, PolyPeptide, CordenPharma, and others. The top five manufacturers together account for 40% of the market share, with the largest manufacturer being Bachem with 17%. At the sales level, North America is the largest sales market with a market share of over 50%, followed by Europe and China with 33% and 9% respectively.
This report aims to provide a comprehensive presentation of the global market for Peptide CDMO, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Peptide CDMO by region & country, by Type, and by Application.
The Peptide CDMO market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide CDMO.
Market Segmentation
By Company
Bachem
PolyPeptide
CordenPharma
AmbioPharm
USV Peptides
Thermofischer
Bio Basic
JPT
Genscript
Xinbang Pharma
ScinoPharm
SN Biopharm
CBL
Piramal Pharma
CPC Scientific
Segment by Type
APIs and Intermediates
FDF
Segment by Application
Commercial
Academic Research
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Peptide CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Peptide CDMO in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Peptide CDMO in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Index